- Bio Protocol funds an $80,000 human trial for brain health and receives CLAW royalty tokens.
- Staked BIO tokens rise to 125 million, tightening supply and increasing demand.
- A harmonic chart pattern signals a potential BIO price rally toward $0.1787.
Bio Protocol (BIO) has regained strong momentum after a sharp pullback earlier this month, rising to a six-month high of $0.1514 before settling near $0.138.
The rebound follows a series of bullish catalysts, from tangible biotech partnerships to increased staking activity, while traders are now eyeing technical signals that suggest further upside.
BIO price recovery gains renewed momentum
After dipping to $0.0962 during the recent correction, BIO staged an impressive recovery of more than 50% in a matter of days.
The robust rebound comes while the broader crypto market has faced selling pressure, yet Bio Protocol managed to move against the trend.
At the time of reporting, the token was trading nearly 100% higher for the month, underscoring its growing resilience.
Trading activity has intensified as well. Daily volumes surged by more than 700% last week, surpassing $440 million as new investors flowed in.
This sharp increase in liquidity has reinforced confidence in BIO’s market depth, making it more attractive to both retail and institutional traders.
Clinical trial financing lifts sentiment
One of the strongest drivers of BIO’s rally is the announcement of its first major biotech initiative.
Through its partner Cerebrum DAO, the Bio Protocol community approved $80,000 in funding for a Phase 2 human trial of Percepta, a candidate targeting memory loss and neurodegeneration.
Big week in the Biosphere 🧪
• Launched Bio Markets w/ real-time DeSci analytics & BioAgent trading coming
• 125M+ $BIO staked + 1M BioXP Boost
• Funding human trial for Percepta $CLAW
• Molecule V2 DeSci equity
• $BeeARD psilocybin derivativeRead the full weekly update: https://t.co/l5lH2Utcjo
— Bio Protocol (@BioProtocol) August 17, 2025
That deal not only gives Bio Protocol direct exposure to real-world biotech outcomes but also provides CLAW tokens.
Those CLAW tokens are tied to royalties from Percepta sales, creating a potential revenue-sharing mechanism that differentiates BIO from many speculative altcoins.
Investors see this as validation that the project is delivering on its promise to bridge decentralized financing and biotech innovation.
Staking reduces supply pressure
Another price-supportive factor is steady growth in BIO token staking.
The amount of BIO staked has climbed to 125 million tokens, representing roughly 3.5% of the circulating supply.
This marks a significant jump from 25 million staked tokens earlier in August.
Stakers earn BioXP, which unlocks access to new ecosystem assets such as CLAW. More importantly, staking removes liquid supply from exchanges.
As a result, rising demand has a magnified price impact. Traders are already comparing the setup to past DeFi tokens where similar dynamics triggered explosive rallies.
Technical setup points to higher targets
Technically, BIO has cleared several key resistance levels. It moved above the 7-day simple moving average at $0.116 and broke the 23.6% Fibonacci retracement at $0.128.
Next resistance appears near $0.145, with momentum indicators showing strong buying pressure despite the relative strength index hovering near overbought territory.
Adding to the bullish outlook, analysts have identified a harmonic ABCD pattern forming on the four-hour chart.
The ABCD pattern began with a rally from $0.0559 to $0.0956, followed by a pullback and then a bullish CD leg.
Extension of that structure projects an upside target near $0.18, a level traders are monitoring as a potential take-profit zone.
Outlook remains cautiously bullish
While the harmonic setup suggests further upside, traders remain mindful of the risk of consolidation.
Failure to hold above the 50-period moving average—currently near $0.1159—could open the door to short-term corrections.
Still, the combination of real-world utility, staking-driven scarcity, and a favorable technical structure has created a strongly bullish sentiment.
Bio Protocol’s six-month high is a notable milestone for a token launched less than a year ago.
Whether the rally can be sustained will depend on the Percepta study’s results and broader adoption of decentralized science models.